ATX-559

N/A

Report date: 2026/01/24 20:00:19
NMEFirst In Class

Base Information

Drug NameATX-559
Drug Alias NameATX-559
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP-dependent RNA helicase A inhibitors
TargetsATP-dependent RNA helicase A
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsRectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAccent Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAccent Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursEndometrial NeoplasmsRectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A